Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

PALO ALTO, Calif., July 24, 2023 /PRNewswire/ — Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate. The DAYLIGHT study was a randomized, double-masked, active comparator-controlled…

Click here to view original post

Advertisement — Advertise with Biotech Networks